$CLBT earnings report

Q3 2026 revenue of $149,022 thousand, up 18% year-over-year; ARR of $528.5 million, up 20%; adjusted EBITDA margin of 36.0%; full-year adjusted EBITDA outlook raised to $163 million to $166 million. AlphAI read Cellebrite DI's Q3 FY2026 filing as strong. 2 quarters are on record below.

Earnings today

CLBT reports today, Nov 12, 2026.

Q3 FY2026

AlphAI · Earnings readCLBT · Q3 2026 · ended 2026-09-30

Q3 2026 revenue of $149,022 thousand, up 18% year-over-year; ARR of $528.5 million, up 20%; adjusted EBITDA margin of 36.0%; full-year adjusted EBITDA outlook raised to $163 million to $166 million

✓Strong quarter

The filing prints 20% ARR growth, 18% revenue growth, GAAP and non-GAAP operating income up year-over-year, quarterly free cash flow of $51,797 thousand against $29,950 thousand, and a raised full-year adjusted EBITDA range. Nine-month GAAP operating income and GAAP net income are below the prior-year nine months, and the Corellium acquisition remains under CFIUS review.

Revenue
$149M
up 18% year-over-year y/y
Subscription services (revenue line, three months ended Sep 30, 2026)
$101M
Gross margin · GAAP
81.2%
EPS · non-GAAP
$0.17
Q4 2026 and full-year 2026, as of 11/12/26 outlook
Q4 2026: $145 million - $150 million; full-year 2026: $553 million - $558 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total Annual Recurring Revenue (ARR), Sep 30, 2026other$528.5M–up 20% year-over-year
Recurring revenue dollar-based net retention rate, Q3 2026other116%––
Revenue, three months ended Sep 30, 2026GAAP$149.0M–up 18% year-over-year
Total subscription revenue, three months ended Sep 30, 2026GAAP$134.9M–a year-over-year increase of 20%
Subscription services revenue, three months ended Sep 30, 2026GAAP$101.2M––
Term-license revenue, three months ended Sep 30, 2026GAAP$33.74M––
Other non-recurring revenue, three months ended Sep 30, 2026GAAP$6.42M––
Professional services revenue, three months ended Sep 30, 2026GAAP$7.69M––
Total cost of revenue, three months ended Sep 30, 2026GAAP$27.98M––
Gross profit, three months ended Sep 30, 2026GAAP$121.0M––
Gross margin, three months ended Sep 30, 2026GAAP81.2%––
Non-GAAP gross profit, three months ended Sep 30, 2026non-GAAP$127.7M––
Non-GAAP gross profit margin, three months ended Sep 30, 2026non-GAAP85.7%––
Research and development, net, three months ended Sep 30, 2026GAAP$36.39M––
Sales and marketing, three months ended Sep 30, 2026GAAP$36.83M––
General and administrative, three months ended Sep 30, 2026GAAP$20.95M––
Total operating expenses, three months ended Sep 30, 2026GAAP$94.17M––
Operating income, three months ended Sep 30, 2026GAAP$26.88M––
Operating margin, three months ended Sep 30, 2026GAAP18.0%––
Non-GAAP operating income, three months ended Sep 30, 2026non-GAAP$51.53M––
Non-GAAP operating margin, three months ended Sep 30, 2026non-GAAP34.6%––
Financial income, net, three months ended Sep 30, 2026GAAP$4.87M––
Tax expense, three months ended Sep 30, 2026GAAP$5.08M––
Net income, three months ended Sep 30, 2026GAAP$26.66M––
Non-GAAP net income, three months ended Sep 30, 2026non-GAAP$45.55M––
Diluted earnings per share, three months ended Sep 30, 2026GAAP$0.10––
Non-GAAP diluted earnings per share, three months ended Sep 30, 2026non-GAAP$0.17––
Adjusted EBITDA, three months ended Sep 30, 2026non-GAAP$53.63M––
Adjusted EBITDA margin, three months ended Sep 30, 2026non-GAAP36.0%––
Net cash provided by operating activities, three months ended Sep 30, 2026GAAP$56.58M––
Free cash flow, three months ended Sep 30, 2026non-GAAP$51.80M––
Free cash flow margin, three months ended Sep 30, 2026non-GAAP34.8%––
Free cash flow, trailing twelve months ended Sep 30, 2026non-GAAP$166.0M––
Free cash flow margin, trailing twelve months ended Sep 30, 2026non-GAAP30.9%––
Revenue, nine months ended Sep 30, 2026GAAP$408.5M––
Gross profit, nine months ended Sep 30, 2026GAAP$332.9M––
Gross margin, nine months ended Sep 30, 2026GAAP81.5%––
Operating income, nine months ended Sep 30, 2026GAAP$42.94M––
Operating margin, nine months ended Sep 30, 2026GAAP10.5%––
Net income, nine months ended Sep 30, 2026GAAP$43.97M––
Diluted earnings per share, nine months ended Sep 30, 2026GAAP$0.17––
Non-GAAP operating income, nine months ended Sep 30, 2026non-GAAP$109.9M––
Non-GAAP operating margin, nine months ended Sep 30, 2026non-GAAP26.9%––
Non-GAAP net income, nine months ended Sep 30, 2026non-GAAP$105.9M––
Non-GAAP diluted earnings per share, nine months ended Sep 30, 2026non-GAAP$0.40––
Adjusted EBITDA, nine months ended Sep 30, 2026non-GAAP$116.0M––
Adjusted EBITDA margin, nine months ended Sep 30, 2026non-GAAP28.4%––
Net cash provided by operating activities, nine months ended Sep 30, 2026GAAP$94.06M––
Free cash flow, nine months ended Sep 30, 2026non-GAAP$83.16M––
Free cash flow margin, nine months ended Sep 30, 2026non-GAAP20.4%––

Segments

SegmentRevenueq/qy/y
Subscription services (revenue line, three months ended Sep 30, 2026)The filing prints the prior-year figure of $84,195 thousand but no percentage change for this line and no driver specific to it.$101.2M––
Term-license (revenue line, three months ended Sep 30, 2026)The filing prints the prior-year figure of $28,531 thousand but no percentage change or driver specific to this line. The CFO states that the full-year revenue targets reflect less hardware revenue compared with the third quarter.$33.74M––
Other non-recurring (revenue line, three months ended Sep 30, 2026)The filing prints the prior-year figure of $5,504 thousand but no percentage change or driver specific to this line.$6.42M––
Professional services (revenue line, three months ended Sep 30, 2026)The filing prints the prior-year figure of $7,799 thousand but no percentage change or driver specific to this line.$7.69M––

Q4 2026 and full-year 2026, as of 11/12/26 outlook

  • RevenueQ4 2026: $145 million - $150 million; full-year 2026: $553 million - $558 million
  • NoteFull-year 2026 ARR: $550 million - $560 million (reaffirmed per the CFO)
  • NoteFull-year 2026 ARR annual growth: 14% - 16%
  • NoteQ4 2026 annual growth of revenue: 13% - 16%
  • NoteFull-year 2026 annual growth of revenue: 16% - 17%
  • NoteQ4 2026 adjusted EBITDA: $47 million - $50 million
  • NoteFull-year 2026 adjusted EBITDA: $163 million - $166 million (raised per the release)
  • NoteQ4 2026 adjusted EBITDA margin: 32% - 33%
  • NoteFull-year 2026 adjusted EBITDA margin: 29% - 30%
  • NoteFull-year 2026 free cash flow margin: approximately 30%

Capital returns

  • The release prints no share repurchase or dividend figures for the period.
  • Proceeds from exercise of options to shares: $1,318 thousand (three months ended Sep 30, 2026) against $3,958 thousand (prior-year quarter); $5,569 thousand (nine months 2026) against $19,075 thousand (nine months 2025).
  • Proceeds from Employee Share Purchase Plan: $1,300 thousand (three months 2026) against $1,309 thousand (prior-year quarter); $4,168 thousand (nine months 2026) against $3,638 thousand (nine months 2025).

What drove it

  • The CEO attributes the topline expansion to strong international performance, another acceleration in U.S. Federal, and Genesis gaining traction in its first full quarter.
  • The CEO states that the combination of revenue growth and prudent investment enabled a meaningful increase in operating profitability and free cash flow.
  • The CFO states that the third-quarter free cash flow reflects strong operating results.
  • The CFO states that the full-year revenue targets were fine-tuned to reflect more ratable revenue from cloud and AI and less hardware revenue compared with the third quarter.
  • The CFO states that the adjusted EBITDA outlook was raised to reflect the outperformance from the third quarter.
  • Amortization of intangible assets rose to $7,244 thousand in the quarter from $934 thousand in the prior-year quarter, as printed in the non-GAAP reconciliation.

Concerns

  • Nine-month GAAP operating income of $42,943 thousand is below $45,675 thousand in the prior-year nine months, and nine-month GAAP net income of $43,965 thousand is below $57,065 thousand. Non-GAAP operating income for the same period rose to $109,921 thousand from $84,165 thousand. The two measures move in opposite directions over the nine months.
  • Nine-month GAAP diluted EPS is $0.17 against $0.23 in the prior-year period, while non-GAAP diluted EPS is $0.40 against $0.37.
  • Gross margin on a GAAP basis is 81.2% for the quarter against 83.9% in the prior-year quarter, and 81.5% for the nine months against 84.0%.
  • Acquisition of Corellium remains under review by CFIUS. The release states the company is seeking to address CFIUS concerns in lieu of potential divestment, has not received a final and binding decision, and cannot predict the outcome.
  • Tax expense for the quarter is $5,085 thousand against $4,099 thousand in the prior-year quarter, and nine-month tax expense is $12,597 thousand against $7,342 thousand.
  • Trade receivables increased by $(29,132) thousand in the quarter and $(34,761) thousand in the nine months within operating cash flow.

What to watch

  • Q4 2026 revenue of $145 million - $150 million and full-year revenue of $553 million - $558 million, against the nine-month revenue of $408,461 thousand.
  • Full-year ARR of $550 million - $560 million, against ARR of $528.5 million at Sep 30, 2026.
  • Q4 2026 adjusted EBITDA margin of 32% - 33%, against the 36.0% adjusted EBITDA margin printed for the third quarter.
  • The CFIUS review of the Corellium acquisition and the outcome of the proposed redomiciliation to the United States, which is subject to shareholder and regulatory approvals.
  • Continued development of Genesis, which the release describes as the foundation for the next-generation platform, and the proportion of ratable cloud and AI revenue against hardware revenue.
  • The 2027 planning cycle, which the release says will focus on durable, profitable ARR growth and further improvement in free cash flow margin.

Balance sheet and cash flow

  • Cash and cash equivalents: $223,055 thousand at Sep 30, 2026 against $124,457 thousand at Dec 31, 2025.
  • Short-term deposits: $121,207 thousand at Sep 30, 2026 against $161,049 thousand at Dec 31, 2025.
  • Marketable securities, current: $139,607 thousand at Sep 30, 2026 against $151,544 thousand at Dec 31, 2025.
  • Marketable securities, non-current: $109,410 thousand at Sep 30, 2026 against $97,959 thousand at Dec 31, 2025.
  • Total assets: $1,068,486 thousand at Sep 30, 2026 against $938,852 thousand at Dec 31, 2025.
  • Total liabilities: $489,179 thousand at Sep 30, 2026 against $454,534 thousand at Dec 31, 2025.
  • Total shareholders' equity: $579,307 thousand at Sep 30, 2026 against $484,318 thousand at Dec 31, 2025.
  • Deferred revenues, current: $295,513 thousand at Sep 30, 2026 against $277,583 thousand at Dec 31, 2025.
  • Intangible assets, net: $117,928 thousand at Sep 30, 2026 against $81,469 thousand at Dec 31, 2025.
  • Goodwill: $119,559 thousand at both Sep 30, 2026 and Dec 31, 2025.
  • The release prints no borrowings or debt balance.
  • Nine months 2026 cash flow: purchase of intangible assets $(24,089) thousand (nine months 2025: none printed); cash paid in conjunction with acquisitions, net of acquired cash, $(15,278) thousand (nine months 2025: none printed).
  • Trade receivables increase in the nine months 2026 operating cash flow reconciliation: $(34,761) thousand, against $(20,435) thousand in the nine months 2025.
  • Free cash flow for the quarters of 2026 as printed: Q3 $51,797 thousand; Q2 $14,521 thousand; Q1 $16,844 thousand; trailing twelve months $166,017 thousand.

Analysis

Cellebrite reported third-quarter 2026 revenue of $149,022 thousand, up 18% from $126,029 thousand, with subscription revenue of $134,905 thousand, up 20%. Total ARR was $528.5 million, up 20% year-over-year, and the recurring revenue dollar-based net retention rate was 116%. Within the revenue table, total subscription grew from $112,726 thousand to $134,905 thousand, while professional services was nearly flat at $7,692 thousand against $7,799 thousand. The release does not print percentage changes for the individual revenue lines other than total subscription, so the mix shift between subscription services, term-license and other lines can be read only from the printed figures.

Profitability improved on the non-GAAP and quarterly GAAP lines. GAAP operating income rose to $26,875 thousand from $18,990 thousand, with an operating margin of 18.0% against 15.1%. Non-GAAP operating income rose to $51,530 thousand from $35,970 thousand, a 34.6% margin against 28.5%. Adjusted EBITDA was $53,625 thousand, a 36.0% margin against 29.9%. GAAP gross margin fell to 81.2% from 83.9%, while the release prints a non-GAAP gross profit margin of 85.7%. Amortization of intangible assets was $7,244 thousand in the quarter against $934 thousand a year earlier, and the release presents it as a non-GAAP adjustment. Research and development rose to $36,387 thousand from $28,124 thousand, while sales and marketing fell to $36,831 thousand from $38,800 thousand.

For the nine months, the picture is mixed. Revenue was $408,461 thousand against $346,854 thousand, and non-GAAP operating income was $109,921 thousand against $84,165 thousand. GAAP operating income was $42,943 thousand against $45,675 thousand, GAAP net income was $43,965 thousand against $57,065 thousand, and GAAP diluted EPS was $0.17 against $0.23. The release does not explain the nine-month GAAP decline beyond the non-GAAP adjustments it prints.

Cash generation was the strongest part of the quarter. Operating cash flow was $56,581 thousand and free cash flow was $51,797 thousand, against $33,272 thousand and $29,950 thousand. Free cash flow for the trailing twelve months was $166,017 thousand, a 30.9% margin. Cash and cash equivalents rose to $223,055 thousand from $124,457 thousand at December 31, 2025, and total assets increased to $1,068,486 thousand. The release prints no borrowings. Share repurchases and dividends are not printed.

The outlook has two moves. The company reaffirmed full-year ARR of $550 million to $560 million and fine-tuned full-year revenue to $553 million to $558 million, which the CFO attributes to more ratable cloud and AI revenue and less hardware revenue than in the third quarter. Full-year adjusted EBITDA was raised to $163 million to $166 million, and the release describes this as reflecting third-quarter outperformance. Fourth-quarter guidance is revenue of $145 million to $150 million and adjusted EBITDA of $47 million to $50 million. No prior outlook was supplied with this filing, so no comparison against earlier guidance is made here. The Corellium acquisition remains under CFIUS review and the redomiciliation to the United States remains subject to shareholder and regulatory approvals.

Management, verbatim

Cellebrite executed better in the third quarter, with ARR, revenue and adjusted EBITDA all finishing above our targets.

Shiv Ramji, Chief Executive Officer

Cellebrite's third-quarter free cash flow of $51.8 million reflects our strong operating results.

David Barter, Chief Financial Officer

As a result of our strong third-quarter performance, we have raised our 2026 adjusted EBITDA outlook.

Shiv Ramji, Chief Executive Officer

Not in the filing

stated, not guessed
  • Prior-year and prior-quarter percentage changes for the subscription services, term-license, other non-recurring and professional services revenue lines.
  • Prior-year percentage change for gross profit, operating expenses, operating income, net income, adjusted EBITDA and free cash flow in dollar terms.
  • Prior-quarter (Q2 2026) figures for the income statement lines; the release prints only the three-month current and prior-year periods and the nine-month periods.
  • Revenue or ARR by geography, by business line, or by segment beyond the four revenue lines in the income statement.
  • Prior-year ARR and prior-year net retention rate.
  • Prior-year full-year revenue, needed to confirm the printed full-year growth range.
  • Share repurchase and dividend amounts; the release prints none.
  • Debt balance or borrowings; the release prints none.
  • Previous period outlook; no prior guidance was supplied, so vs_prior_guidance is empty.
  • Consensus estimates, analyst expectations and share price reaction; not in the document.
  • Prior-year Q3 2025 cash and cash equivalents and total assets at the same date.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Q2 FY2026

AlphAI · Earnings readCLBT · Q2 2026 · ended June 30, 2026

Cellebrite reports second-quarter 2026 revenue growth of 16% year-over-year, misses its ARR target, lowers full-year ARR and revenue outlook, and raises its adjusted EBITDA target.

→Mixed quarter

Revenue grew 16% year-over-year and ARR grew 21%, but management said ARR was below expectations amid longer sales cycles and lower-than-anticipated Inseyets expansion. The company reduced FY26 ARR and revenue expectations while increasing its adjusted EBITDA outlook.

Revenue
$131M
up 16% year-over-year y/y
Gross margin · GAAP
80.8%
EPS · non-GAAP
$0.11
Third-Quarter 2026 and Full-Year 2026 Expectations (as of 08/13/26) outlook
Third-Quarter 2026: $145M – $148M; Full-Year 2026: $555M – $561M

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total Annual Recurring Revenue (ARR)other$507.8M–up 21% year-over-year
Recurring revenue dollar-based net retention rateother117%up 2 pts. over Q1–
RevenueGAAP$131.1M–up 16% year-over-year
Subscription revenueGAAP$119.5M–a year-over-year increase of 16%
Subscription services revenueGAAP$97.69M––
Term-license revenueGAAP$21.80M––
Other non-recurring revenueGAAP$3.91M––
Professional services revenueGAAP$7.74M––
Gross profitGAAP$105.9M––
Gross marginGAAP80.8%––
Gross profitnon-GAAP$112.1M––
Gross profit marginnon-GAAP85.5%––
Operating expensesGAAP$98.98M––
Research and development, netGAAP$35.96M––
Sales and marketingGAAP$43.75M––
General and administrativeGAAP$19.27M––
Operating incomeGAAP$6.95M––
Operating marginGAAP5.3%––
Operating incomenon-GAAP$29.80M––
Operating marginnon-GAAP22.7%––
Net incomeGAAP$6.4M––
Net incomenon-GAAP$29.7M––
Diluted earnings per shareGAAP$0.02––
Diluted earnings per sharenon-GAAP$0.11––
Adjusted EBITDAnon-GAAP$31.8M––
Adjusted EBITDA marginnon-GAAP24.2%––
Cash flow from operating activitiesGAAP$17.59M––
Free cash flownon-GAAP$14.52M––
Free cash flow marginnon-GAAP11.1%––
Free cash flow for the trailing twelve monthsnon-GAAP$144.2M––
Free cash flow margin for the trailing twelve monthsnon-GAAP28.0%––
Six-month revenueGAAP$259.4M––
Six-month gross marginGAAP81.6%––
Six-month operating incomeGAAP$16.07M––
Six-month net incomeGAAP$17.31M––
Six-month adjusted EBITDAnon-GAAP$62.41M––
Six-month free cash flownon-GAAP$31.36M––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Third-Quarter 2026 and Full-Year 2026 Expectations (as of 08/13/26) outlook

  • RevenueThird-Quarter 2026: $145M – $148M; Full-Year 2026: $555M – $561M
  • NoteARR: Third-Quarter 2026 $524M – $528M; Full-Year 2026 $550M – $560M
  • NoteARR annual growth: Third-Quarter 2026 19% – 20%; Full-Year 2026 14% – 16%
  • NoteRevenue annual growth: Third-Quarter 2026 15% – 17%; Full-Year 2026 17% – 18%
  • NoteAdjusted EBITDA: Third-Quarter 2026 $42M – $45M; Full-Year 2026 $153M – $159M
  • NoteAdjusted EBITDA margin: Third-Quarter 2026 29% – 30%; Full-Year 2026 ~28%

What drove it

  • Management cited healthy second-quarter growth in Asia-Pacific, EMEA and U.S. Federal.
  • Cellebrite achieved early monetization for Genesis in the second quarter after its official launch on June 10th.
  • Management reported customer adoption for Guardian Investigate, CFID for drone forensics and Advanced Unlocks.
  • The company signed its first significant FedRAMP deal for Guardian, its SaaS-based evidence management solution delivered through the Cellebrite Government Cloud.
  • Newer products contributed more meaningfully to net new ARR than a year ago, according to the CFO.

Concerns

  • ARR came in below management’s expectations.
  • Management cited longer sales cycles and less expansion from Inseyets conversions than anticipated.
  • GAAP gross margin was 80.8%, compared with 84.4% in the prior-year quarter.
  • GAAP operating income was $6,949 (U.S. Dollars in thousands), compared with $14,417 (U.S. Dollars in thousands) in the prior-year quarter.
  • Free cash flow was $14,521 (U.S. Dollars in thousands), compared with $28,975 (U.S. Dollars in thousands) in the prior-year quarter.
  • The company lowered FY26 ARR and revenue outlook.

What to watch

  • Execution actions intended to address longer sales cycles and Inseyets expansion.
  • Genesis adoption, product enhancements and further monetization since the start of the third quarter.
  • The near-term contribution from newer products, given elongated sales cycles and additional product introductions anticipated for later this year.
  • The expected stronger second-half free cash flow performance.
  • Delivery against third-quarter ARR of $524M – $528M, revenue of $145M – $148M and adjusted EBITDA of $42M – $45M.

Balance sheet and cash flow

  • Cash and cash equivalents: $141,250 (U.S. Dollars in thousands) as of June 30, 2026; $124,457 (U.S. Dollars in thousands) as of December 31, 2025.
  • Short-term deposits: $146,759 (U.S. Dollars in thousands) as of June 30, 2026; $161,049 (U.S. Dollars in thousands) as of December 31, 2025.
  • Marketable securities: $154,522 (U.S. Dollars in thousands) current and $103,185 (U.S. Dollars in thousands) non-current as of June 30, 2026.
  • Total assets: $994,311 (U.S. Dollars in thousands) as of June 30, 2026.
  • Total liabilities: $456,214 (U.S. Dollars in thousands) as of June 30, 2026.
  • Total shareholders’ equity: $538,097 (U.S. Dollars in thousands) as of June 30, 2026.
  • Net cash provided by operating activities: $17,589 (U.S. Dollars in thousands) for the three months ended June 30, 2026; $37,474 (U.S. Dollars in thousands) for the six months ended June 30, 2026.
  • Capital expenditures: $(3,068) (U.S. Dollars in thousands) for the three months ended June 30, 2026; $(6,109) (U.S. Dollars in thousands) for the six months ended June 30, 2026.
  • Cash paid in conjunction with acquisitions, net of acquired cash: $(15,278) (U.S. Dollars in thousands) for the six months ended June 30, 2026.
  • Purchase of Intangible assets: $(8,560) (U.S. Dollars in thousands) for the three months ended June 30, 2026; $(15,619) (U.S. Dollars in thousands) for the six months ended June 30, 2026.

Analysis

Cellebrite delivered $131.1 million of second-quarter revenue, up 16% year-over-year, and ARR of $507.8 million, up 21% year-over-year. Recurring revenue dollar-based net retention was 117%, up 2 pts. over Q1. Management identified healthy growth in Asia-Pacific, EMEA and U.S. Federal, while newer products contributed more meaningfully to net new ARR than a year earlier.

The central issue was ARR execution. Management said ARR fell below its expectation because sales cycles were longer and Inseyets conversions generated less expansion than anticipated. The company also adopted a more measured near-term view of contributions from newer products because of elongated sales cycles and the timing of additional product launches later in the year. These factors drove a reduction to the FY26 ARR and revenue outlook.

Profitability showed a material GAAP decline versus the prior-year quarter. GAAP gross margin was 80.8%, versus 84.4%, while GAAP operating income was $6,949 (U.S. Dollars in thousands), versus $14,417 (U.S. Dollars in thousands), and GAAP net income was $6,371 (U.S. Dollars in thousands), versus $19,476 (U.S. Dollars in thousands). Non-GAAP operating income increased to $29,805 (U.S. Dollars in thousands) from $26,224 (U.S. Dollars in thousands), although non-GAAP operating margin was 22.7%, compared with 23.2%. Adjusted EBITDA rose to $31,790 (U.S. Dollars in thousands) from $27,885 (U.S. Dollars in thousands), with margin at 24.2%.

Cash generation softened in the quarter. Operating cash flow was $17,589 (U.S. Dollars in thousands), compared with $32,583 (U.S. Dollars in thousands), and free cash flow was $14,521 (U.S. Dollars in thousands), compared with $28,975 (U.S. Dollars in thousands). The company ended June 30 with $141,250 (U.S. Dollars in thousands) of cash and cash equivalents, $146,759 (U.S. Dollars in thousands) of short-term deposits, and marketable securities of $154,522 (U.S. Dollars in thousands) current and $103,185 (U.S. Dollars in thousands) non-current.

For Q3, Cellebrite expects ARR of $524M – $528M, revenue of $145M – $148M, and adjusted EBITDA of $42M – $45M. FY26 expectations call for ARR of $550M – $560M and revenue of $555M – $561M, alongside adjusted EBITDA of $153M – $159M and an adjusted EBITDA margin of ~28%. Management characterized the outlook change as a reset to a more appropriate execution foundation, while stating that operating discipline enabled a higher adjusted EBITDA target and that it anticipates stronger second-half free cash flow.

Management, verbatim

We delivered healthy second-quarter growth in Asia-Pacific, EMEA and U.S. Federal. However, ARR came in below our expectations. We saw longer sales cycles and less expansion from Inseyets conversions than anticipated. We are taking action to improve execution going forward.

Shiv Ramji, CEO

Given these dynamics, in combination with the pace and magnitude of Inseyets expansions, we have lowered our FY26 ARR and revenue outlook. We believe resetting expectations now is the responsible approach and provides a more appropriate foundation from which to execute. At the same time, continued operating discipline has enabled us to raise our FY26 adjusted EBITDA target.

Shiv Ramji, CEO

Although we didn’t deliver against our second-quarter 2026 ARR target, we have continued to make tangible progress in executing Cellebrite’s product strategy, with newer products contributing more meaningfully to net new ARR than a year ago, and we expect that momentum to continue into the second half of the year.

David Barter, CFO

Not in the filing

stated, not guessed
  • Prior-quarter total revenue, gross profit, gross margin, operating income, operating margin, net income, EPS, adjusted EBITDA and adjusted EBITDA margin were not provided.
  • Prior-year ARR and recurring revenue dollar-based net retention rate were not provided.
  • GAAP and non-GAAP tax rates were not provided.
  • Debt balance was not provided.
  • Share repurchases and dividends were not provided.
  • Operating segments and segment revenue were not provided.
  • Prior outlook was not provided, so comparisons of reported results versus prior guidance cannot be made.
  • Full-year and third-quarter gross-margin, operating-expense and tax-rate guidance were not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about CLBT earnings dates

When is Cellebrite DI's next earnings date?
CLBT is scheduled to report on Nov 12, 2026. A company can still move a date. AlphAI publishes its own read of the results within minutes of the filing reaching EDGAR.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.